NeuBase Therapeutics, Inc. (NBSE)

NASDAQ: NBSE · IEX Real-Time Price · USD
0.960
0.008 (0.80%)
At close: May 16, 2022 4:00 PM
0.950
-0.010 (-1.042%)
After-hours:May 16, 2022 5:14 PM EDT
Market Cap31.46M
Revenue (ttm)n/a
Net Income (ttm)-33.47M
Shares Out32.77M
EPS (ttm)-0.98
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,551
Open0.990
Previous Close0.952
Day's Range0.941 - 1.000
52-Week Range0.890 - 5.510
Beta0.40
AnalystsBuy
Price Target15.81 (+1,546.9%)
Earnings DateMay 12, 2022

About NBSE

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myoton...

IndustryBiotechnology
CEODietrich Stephan
Employees33
Stock ExchangeNASDAQ
Ticker SymbolNBSE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for NBSE stock is "Buy." The 12-month stock price forecast is 15.81, which is an increase of 1,546.88% from the latest price.

Price Target
$15.81
(1,546.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022

PITTSBURGH and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address...

4 days ago - GlobeNewsWire

NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

PITTSBURGH and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address...

2 weeks ago - GlobeNewsWire

NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstratin...

PITTSBURGH and CAMBRIDGE, Mass., March 13, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to addre...

2 months ago - GlobeNewsWire

NeuBase to Present at Oppenheimer's 32nd Annual Healthcare Conference

PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to addre...

2 months ago - GlobeNewsWire

NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022

PITTSBURGH and CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to addres...

3 months ago - GlobeNewsWire

NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer

PITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to addres...

4 months ago - GlobeNewsWire

NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors

PITTSBURGH and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to addres...

4 months ago - GlobeNewsWire

NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021

PITTSBURGH and CAMBRIDGE, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to addres...

4 months ago - GlobeNewsWire

NeuBase to Present at the Jefferies London Healthcare Conference

PITTSBURGH, Nov. 03, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base...

6 months ago - GlobeNewsWire

NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference

PITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a n...

7 months ago - GlobeNewsWire

NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the bas...

8 months ago - GlobeNewsWire

NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference

PITTSBURGH, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the bas...

8 months ago - GlobeNewsWire

NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights

PITTSBURGH, Aug. 12, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base...

9 months ago - GlobeNewsWire

NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibitio...

PITTSBURGH, June 08, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of pre...

11 months ago - GlobeNewsWire

NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer

Expansion of management team continues with addition of an industry leader with deep experience in business development, licensing, and strategy in the life-science industry Expansion of management team...

11 months ago - GlobeNewsWire

NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer

Expansion of management team to support the Company's advancement of its first drug candidate into clinical trials next year and growth of therapeutic pipeline Expansion of management team to support th...

11 months ago - GlobeNewsWire

NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021

RBC Capital Markets Virtual Global Healthcare Conference Fireside Chat  at 11:30 a.m. ET on May 19

1 year ago - GlobeNewsWire

NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021

PITTSBURGH, May 13, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of prec...

1 year ago - GlobeNewsWire

NeuBase Therapeutics to Present at the B. Riley Securities' Virtual Neuroscience Conference

PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic me...

1 year ago - GlobeNewsWire

NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Addit...

PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic m...

1 year ago - GlobeNewsWire

NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock

PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic me...

1 year ago - GlobeNewsWire

NeuBase Therapeutics Announces Proposed Public Offering of Common Stock

PITTSBURGH, April 21, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic me...

1 year ago - GlobeNewsWire

Why NeuBase Therapeutics Popped by 16.5% on Friday

One of its investors praised the company in a quarterly performance update.

1 year ago - The Motley Fool

David Einhorn's Value Strategy Yields Results While Shorts Drag

David Einhorn (Trades, Portfolio)'s hedge fund, Greenlight Capital, ended 2020 on a high note. After a rough start to the year, Greenlight added 25% in the fourth quarter of 2020, making it the best qua...

Other symbols:GRBKHONREZI
1 year ago - GuruFocus

NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of syn...

1 year ago - GlobeNewsWire